Cargando…

How osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells

Dexamethasone (dexa) is commonly used to stimulate osteogenic differentiation of mesenchymal stem/stromal cells (MSCs) in vitro. However, it is paradoxical that glucocorticoids (GCs) such as dexa lead to bone loss and increased fracture risk in patients undergoing glucocorticoid therapy, causing glu...

Descripción completa

Detalles Bibliográficos
Autores principales: Umrath, Felix, Pfeifer, Achim, Cen, Wanjing, Danalache, Marina, Reinert, Siegmar, Alexander, Dorothea, Naros, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660266/
https://www.ncbi.nlm.nih.gov/pubmed/36393863
http://dx.doi.org/10.3389/fcell.2022.953516
_version_ 1784830385056645120
author Umrath, Felix
Pfeifer, Achim
Cen, Wanjing
Danalache, Marina
Reinert, Siegmar
Alexander, Dorothea
Naros, Andreas
author_facet Umrath, Felix
Pfeifer, Achim
Cen, Wanjing
Danalache, Marina
Reinert, Siegmar
Alexander, Dorothea
Naros, Andreas
author_sort Umrath, Felix
collection PubMed
description Dexamethasone (dexa) is commonly used to stimulate osteogenic differentiation of mesenchymal stem/stromal cells (MSCs) in vitro. However, it is paradoxical that glucocorticoids (GCs) such as dexa lead to bone loss and increased fracture risk in patients undergoing glucocorticoid therapy, causing glucocorticoid-induced osteoporosis (GIOP). In a recent publication, we demonstrated that osteogenic differentiation of progenitor cells isolated from jaw periosteal tissue (JPCs) does not depend on dexa, if the medium is supplemented with human platelet lysate (hPL) instead of fetal bovine serum (FBS). This allows the in vitro conditions to be much closer to the natural situation in vivo and enables us to compare osteogenic differentiation with and without dexa. In the present study, we demonstrate that the absence of dexa did not reduce mineralization capacity, but instead slightly improved the osteogenic differentiation of jaw periosteal cells. On the other hand, we show that dexa supplementation strongly alters the gene expression, extracellular matrix (ECM), and cellular communication of jaw periosteal cells. The secretome of periosteal cells previously treated with an osteogenic medium with and without dexa was used to investigate the changes in paracrine secretion caused by dexa. Dexa altered the secretion of several cytokines by jaw periosteal cells and strongly induced osteoclast differentiation of peripheral blood mononuclear cells (PBMCs). This study demonstrates how dexa supplementation can influence the outcome of in vitro studies and highlights a possible role of periosteal cells in the pathogenesis of glucocorticoid-induced osteoporosis. The methods used here can serve as a model for studying bone formation, fracture healing, and various pathological conditions such as (glucocorticoid-induced) osteoporosis, osteoarthritis, bone cancer, and others, in which the interactions of osteoblasts with surrounding cells play a key role.
format Online
Article
Text
id pubmed-9660266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96602662022-11-15 How osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells Umrath, Felix Pfeifer, Achim Cen, Wanjing Danalache, Marina Reinert, Siegmar Alexander, Dorothea Naros, Andreas Front Cell Dev Biol Cell and Developmental Biology Dexamethasone (dexa) is commonly used to stimulate osteogenic differentiation of mesenchymal stem/stromal cells (MSCs) in vitro. However, it is paradoxical that glucocorticoids (GCs) such as dexa lead to bone loss and increased fracture risk in patients undergoing glucocorticoid therapy, causing glucocorticoid-induced osteoporosis (GIOP). In a recent publication, we demonstrated that osteogenic differentiation of progenitor cells isolated from jaw periosteal tissue (JPCs) does not depend on dexa, if the medium is supplemented with human platelet lysate (hPL) instead of fetal bovine serum (FBS). This allows the in vitro conditions to be much closer to the natural situation in vivo and enables us to compare osteogenic differentiation with and without dexa. In the present study, we demonstrate that the absence of dexa did not reduce mineralization capacity, but instead slightly improved the osteogenic differentiation of jaw periosteal cells. On the other hand, we show that dexa supplementation strongly alters the gene expression, extracellular matrix (ECM), and cellular communication of jaw periosteal cells. The secretome of periosteal cells previously treated with an osteogenic medium with and without dexa was used to investigate the changes in paracrine secretion caused by dexa. Dexa altered the secretion of several cytokines by jaw periosteal cells and strongly induced osteoclast differentiation of peripheral blood mononuclear cells (PBMCs). This study demonstrates how dexa supplementation can influence the outcome of in vitro studies and highlights a possible role of periosteal cells in the pathogenesis of glucocorticoid-induced osteoporosis. The methods used here can serve as a model for studying bone formation, fracture healing, and various pathological conditions such as (glucocorticoid-induced) osteoporosis, osteoarthritis, bone cancer, and others, in which the interactions of osteoblasts with surrounding cells play a key role. Frontiers Media S.A. 2022-10-31 /pmc/articles/PMC9660266/ /pubmed/36393863 http://dx.doi.org/10.3389/fcell.2022.953516 Text en Copyright © 2022 Umrath, Pfeifer, Cen, Danalache, Reinert, Alexander and Naros. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Umrath, Felix
Pfeifer, Achim
Cen, Wanjing
Danalache, Marina
Reinert, Siegmar
Alexander, Dorothea
Naros, Andreas
How osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells
title How osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells
title_full How osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells
title_fullStr How osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells
title_full_unstemmed How osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells
title_short How osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells
title_sort how osteogenic is dexamethasone?—effect of the corticosteroid on the osteogenesis, extracellular matrix, and secretion of osteoclastogenic factors of jaw periosteum-derived mesenchymal stem/stromal cells
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660266/
https://www.ncbi.nlm.nih.gov/pubmed/36393863
http://dx.doi.org/10.3389/fcell.2022.953516
work_keys_str_mv AT umrathfelix howosteogenicisdexamethasoneeffectofthecorticosteroidontheosteogenesisextracellularmatrixandsecretionofosteoclastogenicfactorsofjawperiosteumderivedmesenchymalstemstromalcells
AT pfeiferachim howosteogenicisdexamethasoneeffectofthecorticosteroidontheosteogenesisextracellularmatrixandsecretionofosteoclastogenicfactorsofjawperiosteumderivedmesenchymalstemstromalcells
AT cenwanjing howosteogenicisdexamethasoneeffectofthecorticosteroidontheosteogenesisextracellularmatrixandsecretionofosteoclastogenicfactorsofjawperiosteumderivedmesenchymalstemstromalcells
AT danalachemarina howosteogenicisdexamethasoneeffectofthecorticosteroidontheosteogenesisextracellularmatrixandsecretionofosteoclastogenicfactorsofjawperiosteumderivedmesenchymalstemstromalcells
AT reinertsiegmar howosteogenicisdexamethasoneeffectofthecorticosteroidontheosteogenesisextracellularmatrixandsecretionofosteoclastogenicfactorsofjawperiosteumderivedmesenchymalstemstromalcells
AT alexanderdorothea howosteogenicisdexamethasoneeffectofthecorticosteroidontheosteogenesisextracellularmatrixandsecretionofosteoclastogenicfactorsofjawperiosteumderivedmesenchymalstemstromalcells
AT narosandreas howosteogenicisdexamethasoneeffectofthecorticosteroidontheosteogenesisextracellularmatrixandsecretionofosteoclastogenicfactorsofjawperiosteumderivedmesenchymalstemstromalcells